

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# **FOSUN PHARMA**

## **复星医药**

上海復星醫藥(集團)股份有限公司

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

(Stock Code: 02196)

### **OVERSEAS REGULATORY ANNOUNCEMENT**

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the “Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

**Wu Yifang**

*Chairman*

Shanghai, the PRC

15 January 2024

*As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.*

\* *for identification purposes only*

# **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

## **Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary**

**The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.**

### **I. Overview**

Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd.\* (浙江星浩澎博醫藥有限公司) (“**Xinghao Pengbo**”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. \* (上海復星醫藥（集團）股份有限公司) (the “**Company**” and, together with its subsidiaries/units, the “**Group**”, the same applies below), recently received the approval from the National Medical Products Administration of the People’s Republic of China for clinical trial of XH-S004 tablets (the “**Investigational New Drug**”) for the treatment of non-cystic fibrosis bronchiectasis. Xinghao Pengbo intends to commence a Phase I clinical trial of the Investigational New Drug in China (excluding Hong Kong, Macau and Taiwan for the purpose of this announcement, the same applies below) when the conditions are fulfilled.

### **II. Research Progress of the Investigational New Drug**

The Investigational New Drug is an oral small molecule inhibitor developed by the Group, which is intended to be used for non-cystic fibrosis bronchiectasis and other inflammatory diseases.

The Investigational New Drug can inhibit the excessive inflammation caused by neutrophils in the airway through inhibiting the activation of neutrophils, thus achieving

the therapeutical potential for treating bronchiectasis. The Investigational New Drug demonstrated potent and selective inhibitory activity on the target with good tolerability in preclinical pharmacology and toxicology studies to date.

As of December 2023, the Group has invested approximately RMB 36.53 million (unaudited) in total in the research and development (the “**R&D**”) of the Investigational New Drug at current stage.

As of the date of this announcement, no oral small molecule inhibitor with the same molecular mechanism had been approved for marketing worldwide.

### **III. Risk Warning**

As required by the relevant laws and regulations in China, the Investigational New Drug is subject to undergo a series of clinical studies and be approved by the national drug review authority before it can be marketed. There are certain risks in the R&D of new drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and launch of new drugs is a long-term task involving various uncertainties. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

15 January 2024

*\*For identification purpose only*